A5106077087- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Nutrition and Health in Aging
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Body Composition Measurement Techniques
- Muscle Physiology and Disorders
- Vascular Malformations and Hemangiomas
- T-cell and B-cell Immunology
- Genetic and rare skin diseases.
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Single-cell and spatial transcriptomics
- Cervical Cancer and HPV Research
- Bladder and Urothelial Cancer Treatments
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Hedgehog Signaling Pathway Studies
- Cancer, Lipids, and Metabolism
- Nuclear Structure and Function
- Endometriosis Research and Treatment
- Cancer Risks and Factors
- Genetic factors in colorectal cancer
Maastricht University
2019-2025
Maastricht University Medical Centre
2019-2022
Children's Oncology Group
2019
KU Leuven
2015
The guideline is presented as a detailed review with highlighted recommendations for practical use in the clinic by dermatologists and other healthcare professionals, including general practitioners, clinical geneticists, paediatricians, ophthalmologists, craniomaxillofacial surgeons, neurologists, cardiologists psychologists. does not cover therapeutic (nondermatological) symptoms, mainly focuses on screening follow-up of symptoms. Therapeutic basal cell carcinomas (BCCs) have been...
The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has been shown to be applicable endometrioid ovarian cancer (ENOC), classifying tumors into four molecular subgroups: POLE mutated (POLEmut), mismatch repair deficient (MMRd), p53 abnormal (p53abn), and no specific profile (NSMP). However, the large NSMP subgroup in ENOC limits its clinical applicability. Incorporating estrogen receptor (ER) status improved prognostic accuracy endometrial cancer. Therefore, this study...
We introduce a novel per-gene measure of intra-gene DNA methylation variability (IGV) based on the Illumina Infinium HumanMethylation450 platform, which is prognostic independently well-known predictors clinical outcome. Using IGV, we derive robust gene-panel signature for ovarian cancer (OC, n = 221), validates in two independent data sets from Mayo Clinic (n 198) and TCGA 358), with significance p 0.004 both sets. The OC comprised four gene groups, represent distinct biological processes....
Ovarian cancer has the worst overall survival rate of all gynecologic malignancies. For majority patients, 5-year less than 50% hardly improved over last decades. To improve outcome patients with subtypes ovarian cancer, large-scale fundamental and translational research is needed. accommodate these types research, we have established a Dutch nationwide, interdisciplinary infrastructure biobank: Archipelago Cancer Research (AOCR). The AOCR will facilitate enhance interdisciplinary, national,...
Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms improve treatment survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago Ovarian Cancer Research (AOCR) infrastructure, which includes a nationwide biobank. In this study, share our experiences establishing offer guidance for similar initiatives, evaluate AOCR patient cohort. Key challenges included obtaining Data Protection Impact...
<div>Abstract<p>The presence of regulatory T cells (Treg) in solid tumors is known to play a role patient survival ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) 25 Treg-associated genes (<i>CD28</i>, <i>CTLA4</i>, <i>FOXP3</i>, <i>IDO1</i>, <i>IL10</i>, <i>IL10RA</i>, <i>IL15</i>, <i>1L17RA</i>,...
<h3>Introduction/Background</h3> Skeletal muscle depletion in women with advanced ovarian cancer has been associated adverse clinical outcome and survival. To validate earlier results a homogenous population, we analyzed whether decrease skeletal index (SMI) during neo-adjuvant chemotherapy (NACT) is worse patients stage III epithelial cancer, who were included the OVHIPEC trial. <h3>Methodology</h3> Within phase trial, 245 randomized after three cycles of NACT carboplatin paclitaxel to...
<h3>Introduction/Background</h3> In the previous decades, laparoscopic radical hysterectomy (LRH) has been introduced as alternative to abdominal (ARH) in early-stage cervical cancer. 2018, results from first prospective randomised study (the 'LACC' trial) were published, reporting inferior survival patients treated with LRH. Therefore, we aimed evaluate outcomes for ARH and LRH cancer, Netherlands. <h3>Methodology</h3> this retrospective study, diagnosed between 2010 2017 cancer FIGO (2009)...